{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,11,19]],"date-time":"2024-11-19T15:48:10Z","timestamp":1732031290955},"reference-count":11,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2003,6,1]],"date-time":"2003-06-01T00:00:00Z","timestamp":1054425600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2003,6]]},"DOI":"10.1067\/mjd.2003.427","type":"journal-article","created":{"date-parts":[[2003,6,4]],"date-time":"2003-06-04T20:09:55Z","timestamp":1054757395000},"page":"985-986","source":"Crossref","is-referenced-by-count":9,"title":["Cutaneous manifestations of antiviral therapy"],"prefix":"10.1067","volume":"48","author":[{"given":"Elizabeth J.","family":"Phillips","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandra R.","family":"Knowles","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neil","family":"Shear","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1067\/mjd.2003.427_bib1","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1067\/mjd.2002.119105","article-title":"Cutaneous manifestations of antiretroviral therapy","volume":"46","author":"Ward","year":"2002","journal-title":"J Am Acad Dermatol"},{"key":"10.1067\/mjd.2003.427_bib2","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1016\/S0140-6736(99)06102-4","article-title":"Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy","volume":"354","author":"Brinkman","year":"1999","journal-title":"Lancet"},{"key":"10.1067\/mjd.2003.427_bib3","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1517\/13543784.10.8.1443","article-title":"Strategies for treating HIV-related lipodystrophy","volume":"10","author":"Martinez","year":"2001","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1067\/mjd.2003.427_bib4","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1001\/jama.284.4.472","article-title":"Metformin in the treatment of HIV lipodystrophy syndrome: a randomized controlled trail","volume":"284","author":"Hadigan","year":"2000","journal-title":"JAMA"},{"key":"10.1067\/mjd.2003.427_bib5","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1097\/00042560-200109010-00003","article-title":"Failure of a short-term prednisone regimen to prevent nevirapine-associated rash: a double-blind placebo-controlled trial, the GESIDA 09\/99 study","volume":"28","author":"Knobel","year":"2001","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1067\/mjd.2003.427_bib6","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1097\/00002030-200107060-00007","article-title":"Hepatotoxicity in HIV-1-infected patients receiving nevriapine-containing antiretroviral therapy","volume":"15","author":"Mart?nez","year":"2001","journal-title":"AIDS"},{"key":"10.1067\/mjd.2003.427_bib7","first-page":"1153","article-title":"Serious adverse events attributed to nevrirapine regimens for postexposure prophylaxis after HIV exposure-worldwide 1997-2000","volume":"49","author":"Centers for Disease Control and Prevention","year":"2001","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1067\/mjd.2003.427_bib8","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1086\/317536","article-title":"Sex differences in nevirapine rash","volume":"32","author":"Bersoff-Matcha","year":"2001","journal-title":"Clin Infect Dis"},{"key":"10.1067\/mjd.2003.427_bib9","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1016\/S0149-2918(01)80132-6","article-title":"Hypersensitivity reactions during therapy with the nucleoside reverse transcriptase inhibitor abacavir","volume":"10","author":"Hetherington","year":"2001","journal-title":"Clin Ther"},{"key":"10.1067\/mjd.2003.427_bib10","article-title":"Forty eight-week assessment of high-strength T-20 in multi-class experienced patients","author":"Wheat","year":"2002"},{"key":"10.1067\/mjd.2003.427_bib11","series-title":"A preliminary clinical and histological examination of injection site reactions after sequential injections with the HIV fusion inhibitor Enfuvirtide","author":"Myers","year":"2002"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962203700851?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962203700851?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,3,20]],"date-time":"2019-03-20T22:56:30Z","timestamp":1553122590000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962203700851"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,6]]},"references-count":11,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2003,6]]}},"alternative-id":["S0190962203700851"],"URL":"https:\/\/doi.org\/10.1067\/mjd.2003.427","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2003,6]]}}}